The recent completion in North Carolina of a trial study of MDMA-assisted psychotherapy with treatment-resistant patients of Post-Traumatic Stress Disorder (PTSD) marked the re-emergence, after a forty-year break, of formal psychedelic medicine in the USA. The renaissance is now gathering momentum, as similar MDMA/PTSD trials are either on the drawing board or already underway in Switzerland, Israel, Jordan and Canada, in addition to a follow-up trial in the US. All of the studies are being coordinated and funded by MAPS, the Multidisciplinary Association for Psychedelic Studies, which was founded 25 years ago by Dr Rick Doblin and now operates as a substantial not-for-profit, tax-deductible gift status organisation that has international scope and extensive global connections. MAPS is also coordinating and/or supporting other research projects in various parts of the world, into the application of ibogaine for opiate addiction therapy; treatment of anxiety with MDMA, psilocybin and LSD; medical uses of cannabis; and the value of psilocybin for spiritual growth and personal development. As in the USA, social change has brought us back to the point at which there is now scope for formal psychedelic research to take place in Australia, and a new non-profit organisation, PRISM (Psychedelic Research In Science & Medicine), is steadily working towards bringing this potential to fruition.